Ron Bentsur
CIK 1251213 · Chairman & CEO · last filed 2026-07-01
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
KERX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
20TH FL
NEW YORK, NY 10022
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NVCT | Chairman & CEO | 3,688,424 | $18.38 | $67.79M | $2.73M | 51 | 2026-07-01 |
| XAIR | Director | 362 | $2.21 | $800 | -$1.49M | 25 | 2024-11-26 |
| STEMLINE THERAPEUTICS INC (STML) Delisted | Director | 0 | — | — | -$22.4K | 8 | 2020-06-10 |
| KERYX BIOPHARMACEUTICALS INC (KERX) Delisted | Chief Executive Officer | 777,209 | — | — | -$11.23M | 29 | 2015-04-08 |
| XTLB | CEO | 1,005 | $1.78 | $1.8K | $19.9K | 1 | 2007-08-21 |
Recent Filings · Page 5 of 12
115 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-08-16 | NVCT | Buy (P) | +19,669 | $165.2K | EDGAR |
| 2022-07-05 | XAIR | Sell (S) | −40,000 | -$261.1K | EDGAR |
| 2022-06-30 | NVCT | Buy (P) | +4,000 | $46.5K | EDGAR |
| 2022-06-27 | NVCT | Buy (P) | +700 | $8.5K | EDGAR |
| 2022-05-31 | NVCT | Buy (P) | +1,000 | $15.8K | EDGAR |
| 2022-05-23 | NVCT | Buy (P) | +1,200 | $20.1K | EDGAR |
| 2022-05-19 | NVCT | Buy (P) | +2,010 | $39.2K | EDGAR |
| 2022-05-17 | NVCT | Buy (P) | +1,700 | $32.0K | EDGAR |
| 2022-05-13 | NVCT | Buy (P) | +12,245 | $208.0K | EDGAR |
| 2022-04-05 | NVCT | Grant (A) | +120,000 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.